Abraham J Wu1, Elizabeth Garay2, Amanda Foster2, Meier Hsu3, Zhigang Zhang3, Jamie E Chaft4, James Huang5, Kenneth E Rosenzweig6, Andreas Rimner2. 1. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: wua@mskcc.org. 2. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY. 3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. 4. Department of Thoracic Oncology, Memorial Sloan Kettering Cancer Center and Department of Medicine, Weill-Cornell Medical College, New York, NY. 5. Department of Thoracic Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. 6. Department of Radiation Oncology, Mount Sinai Medical Center, New York, NY.
Abstract
INTRODUCTION: Locoregional recurrence after resection of non-small-cell lung cancer (NSCLC) is common. We examined outcomes after definitive radiotherapy (RT) to identify prognostic factors for survival and further recurrence. PATIENTS AND METHODS: We reviewed 152 patients who received RT for locoregional recurrent (LR)-NSCLC, and analyzed subsequent overall survival (OS), locoregional failure (LRF), distant metastasis (DM), and any disease progression (LRF and DM). RESULTS: Two- and 5-year OS were 49% and 28%, respectively. Two- and 5-year LRF, DM, and any disease progression rates were 40% and 45%, 33% and 37%, and 53% and 57%, respectively. Performance status and intensity-modulated RT (IMRT) were independently associated with OS, as was RT dose ≥ 60 Gy. Stage, chemotherapy at recurrence, and surgery to recurrence interval were not independently associated with outcome. Chemotherapy at initial presentation, adenocarcinoma histology, and male sex were independently associated with higher rates of DM. CONCLUSION: To our knowledge, this is the largest reported series of LR-NSCLC treated with definitive RT. Survival appears comparable to or greater than that of primary NSCLC. Subsequent LRF is more common than distant failure. Established prognostic factors for primary NSCLC, such as chemotherapy and stage, were not clearly prognostic in this analysis. IMRT and higher RT doses were associated with improved survival, though IMRT patients were also treated more recently. These data support definitive-intent RT with optimal dose and technique in such patients.
INTRODUCTION: Locoregional recurrence after resection of non-small-cell lung cancer (NSCLC) is common. We examined outcomes after definitive radiotherapy (RT) to identify prognostic factors for survival and further recurrence. PATIENTS AND METHODS: We reviewed 152 patients who received RT for locoregional recurrent (LR)-NSCLC, and analyzed subsequent overall survival (OS), locoregional failure (LRF), distant metastasis (DM), and any disease progression (LRF and DM). RESULTS: Two- and 5-year OS were 49% and 28%, respectively. Two- and 5-year LRF, DM, and any disease progression rates were 40% and 45%, 33% and 37%, and 53% and 57%, respectively. Performance status and intensity-modulated RT (IMRT) were independently associated with OS, as was RT dose ≥ 60 Gy. Stage, chemotherapy at recurrence, and surgery to recurrence interval were not independently associated with outcome. Chemotherapy at initial presentation, adenocarcinoma histology, and male sex were independently associated with higher rates of DM. CONCLUSION: To our knowledge, this is the largest reported series of LR-NSCLC treated with definitive RT. Survival appears comparable to or greater than that of primary NSCLC. Subsequent LRF is more common than distant failure. Established prognostic factors for primary NSCLC, such as chemotherapy and stage, were not clearly prognostic in this analysis. IMRT and higher RT doses were associated with improved survival, though IMRT patients were also treated more recently. These data support definitive-intent RT with optimal dose and technique in such patients.
Authors: Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy Journal: JAMA Date: 2010-03-17 Impact factor: 56.272
Authors: Xu-Wei Cai; Lu-Ying Xu; Li Wang; James A Hayman; Andrew C Chang; Allan Pickens; Kemp B Cease; Mark B Orringer; Feng-Ming Kong Journal: Int J Radiat Oncol Biol Phys Date: 2009-06-18 Impact factor: 7.038
Authors: C A Perez; K Stanley; G Grundy; W Hanson; P Rubin; S Kramer; L W Brady; J E Marks; R Perez-Tamayo; G S Brown; J P Concannon; M Rotman Journal: Cancer Date: 1982-09-15 Impact factor: 6.860
Authors: Walter J Curran; Rebecca Paulus; Corey J Langer; Ritsuko Komaki; Jin S Lee; Stephen Hauser; Benjamin Movsas; Todd Wasserman; Seth A Rosenthal; Elizabeth Gore; Mitchell Machtay; William Sause; James D Cox Journal: J Natl Cancer Inst Date: 2011-09-08 Impact factor: 13.506
Authors: Matthew D Taylor; Alykhan S Nagji; Castigliano M Bhamidipati; Nicholas Theodosakis; Benjamin D Kozower; Christine L Lau; David R Jones Journal: Ann Thorac Surg Date: 2012-04-26 Impact factor: 4.330
Authors: Zhongxing X Liao; Ritsuko R Komaki; Howard D Thames; Helen H Liu; Susan L Tucker; Radhe Mohan; Mary K Martel; Xiong Wei; Kunyu Yang; Edward S Kim; George Blumenschein; Waun Ki Hong; James D Cox Journal: Int J Radiat Oncol Biol Phys Date: 2009-06-08 Impact factor: 7.038
Authors: W J Curran; S H Herbert; P M Stafford; H M Sandler; S A Rosenthal; W G McKenna; E Hughes; M J Dougherty; S Keller Journal: Int J Radiat Oncol Biol Phys Date: 1992 Impact factor: 7.038